Specifications tableSubject areaMedicine, Clinical ResearchMore specific subject areaCardiology, Epidemiology, BiomarkersType of dataTableHow data was acquiredSerum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Czech Republic) together with a DTX 880 Multimode Detector (Beckman Coulter, CA, U.S.A.). Patient data were acquired from national registries and review of patient registries. Hazard ratios were derived from univariable and multivariable Cox proportional hazards models using SPSS 25.0 for Windows.Data formatAnalyzed dataExperimental factorsPlasma CTRP1 levels were measured in 539 patients undergoing coronary angiography. These patients were prospectively followed, and major adverse cardiovascular events cardiovascular events were recorded for up to 8 years.Experimental featuresCTRP1 plasma concentrations were measured by ELISAData source locationFeldkirch, AustriaData accessibilityData is with this article. Raw data are made available for further investigations in collaborative studies.Related research articleA. Muendlein, A. Leiherer, C.H. Saely, J. Ebner, K. Geiger, EM Brandtner, A. Vonbank, P. Fraunberger, H. Drexel, The Novel Adipokine CTRP1 is Significantly Associated with the Incidence of Major Adverse Cardiovascular Events, Atherosclerosis. 286 (2019). [https://doi.org/10.1016/j.atherosclerosis.2019.04.222](10.1016/j.atherosclerosis.2019.04.222){#intref0010}[@bib1].**Value of the data**•The data presented here further characterize included patients by showing the impact of baseline variables on the incidence of major adverse cardiovascular events in patients undergoing coronary angiography, which may differ from the general population.•The data presented here stressed the impact of CTRP1 on future cardiovascular risk beyond its association with traditional coronary risk factors and, therefore, may stimulate further research on the role of CTRP1 in the development of cardiovascular disease.•These data are important, because the existing literature about CTRP1 is still limited, and therefore, they particularly extend the knowledge regarding the association between CTRP1 and cardiovascular disease.

1. Data {#sec1}
=======

A significant association between CTRP1 and major adverse cardiovascular events (MACE) in patients undergoing coronary angiography has been reported in the associated research article [@bib1]. In addition to the baseline characteristics of the selected study population given in the main article, [Table 1](#tbl1){ref-type="table"} of this article shows the impact of most baseline variables on the incidence of MACE. [Table 2](#tbl2){ref-type="table"} shows further data regarding multivariable Cox proportional hazards models adjusting for age, sex, body mass index, type 2 diabetes mellitus, significant coronary artery disease, hypertension, smoking, LDL cholesterol, HDL cholesterol, and estimated glomerular filtration rate and additionally for the extent of coronary artery disease as well as the percentage of left ventricular ejection fraction (model a) or inflammatory markers including fibrinogen and C-reactive protein (model b).Table 1Impact of baseline variables on the incidence of major adverse cardiovascular events.Table 1HR (95%CI)p-valueAge (years)1.20 \[0.96--1.49\]0.116Male gender0.99 \[0.68--1.43\]0.945BMI (kg/m^2^)0.86 \[0.72--1.04\]0.862Metabolic syndrome1.33 \[0.94--1.88\]0.111Type 2 diabetes mellitus1.76 \[1.23--2.50\]0.002Hypertension1.12 \[0.72--1.77\]0.613Smoking1.21 \[0.84--1.74 \]0.302LDL-Cholesterol (mg/dl)0.84 \[0.71--1.00\]0.049HDL-Cholesterol (mg/dl)0.74 \[0.62--0.90\]0.002Triglycerides (mg/dl)1.06 \[0.88--1.26\]0.550eGFR (ml/min/1.73m^2^)0.70 \[0.58--0.85\]\<0.001NAFLD1.14 \[0.79--1.65\]0.482Significant CAD1.65 \[1.12--2.44\]0.012Extent of CAD1.15 \[1.05--1.26\]0.002LVEF (%)0.61 \[0.51--0.73\]\<0.001C-reactive protein (mg/dl)1.46 \[1.23--1.73\]\<0.001Fibrinogen (mg/dl)1.22 \[1.01--1.47\]0.036BNP (pg/dl)1.51 \[1.31--1.75\]\<0.001[^1]Table 2Adjusted associations between CTRP1 quartiles and the incidence of major adverse cardiovascular events - results from multivariable Cox regression analyses.Table 2CTRP1 quartilesQuartile 1Quartile 2Quartile 3Quartile 4p~trend~-valueAdjusted^a^ hazard ratio (95% CI)1^reference^1.98 \[1.12--3.50\]; p = 0.0192.18 \[1.23--3.77\]; p = 0.0051.86 \[1.06--3.27\]; p = 0.0300.036Adjusted^b^ hazard ratio (95% CI)1^reference^1.83 \[1.04--3.23\]; p = 0.0372.16 \[1.25--3.75\]; p = 0.0061.80 \[1.03--3.15\]; p = 0.0380.041[^2]

2. Experimental design, materials and methods {#sec2}
=============================================

The present dataset included 539 consecutive Caucasian patients, who were referred to elective coronary angiography for the evaluation of established or suspected stable CAD at the academic teaching hospital Feldkirch, Austria. Baseline characteristics were obtained as described in the associated main article [@bib1] and in previous reports [@bib2], [@bib3]. In short, the extent of atherosclerosis was defined as the number of ≥50% lesions. Left ventricular function was assessed by 2D echocardiography. Venous blood samples were collected after an overnight fast of 12 h prior to angiography and laboratory measurements were performed from fresh serum or plasma samples or from serum or plasma samples stored at −80 °C. C-reactive protein (CRP) was measured by particle enhanced immunological agglutination (Roche, Switzerland) on a Hitachi Cobas 501. Serum CTRP1 levels were determined using a commercial enzyme-linked immunosorbent assay (ELISA) kit (Biovendor, Brno, Czech Republic; article number: RD191153100R).

During a mean follow-up period of 5.9 ± 2.2 years (with a total of 8 years) cardiovascular events were recorded. Out of the 539 patients initially included in the present study, 15 subjects were lost to follow-up. MACE was defined as a three-point composite of cardiovascular death, nonfatal myocardial infarction, and nonfatal stroke. Time and causes of death were regularly obtained from a national survey (Statistik Austria, Vienna, Austria) or from hospital records.

Hazard ratios (HRs) and 95% confidence intervals of the HRs were derived from univariable and multivariable Cox proportional hazards models; log-transformed continuous variables were z-transformed for these analyses. P-values \<0.05 were considered significant. Statistical analyses were performed with SPSS 25.0 for Windows (IBM, Armonk, New York, USA).

The present study has been approved by the Ethics Committee of the University of Innsbruck, Austria, and written informed consent was given by all participants.
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[^1]: Results of univariate Cox regression analysis. Age, BMI, LDL-C, HDL-C, triglycerides, eGFR, LVEF, C-reactive protein, fibrinogen, and BNP were log-transformed and z-transformed before analysis. Coronary artery stenoses with stenotic narrowing ≥50% were defined as significant CAD. The extent of CAD was defined as the number of ≥50% lesions. BMI, body mass index; eGFR, estimated glomerular filtration rate; NAFLD, non-alcoholic fatty liver disease; CAD, coronary artery disease; LVEF, left ventricular ejection fraction; BNP, brain natriuretic peptide; HR, hazard ratio; CI, confidence interval.

[^2]: Adjustment model ^a^ adjusts for age, sex, BMI, type 2 diabetes mellitus (T2DM), angiographically significant coronary artery disease (CAD), the extent of CAD, percentage of left ventricular ejection fraction (LVEF), hypertension, smoking, LDL cholesterol, HDL cholesterol, and estimated glomerular filtration rate (eGFR); model ^b^ adjusts for age, sex, BMI, type 2 diabetes mellitus (T2DM), angiographically significant coronary artery disease (CAD), hypertension, smoking, LDL cholesterol, HDL cholesterol, estimated glomerular filtration rate, (eGFR), fibrinogen, and C-reactive protein (CRP). Age, BMI, LVEF, LDL cholesterol, HDL cholesterol, eGFR, fibrinogen, and CRP were log-transformed before included in multivariable Cox regression analyses.
